Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with multiple sclerosis (MS) with neurogenic detrusor overactivity proven by urodynamics~* Stable MS with an Expanded Disability Severity Score (EDSS) less than or equal to 6.5~* Voluntary micturitions~* Number of micturitions \> 8 per day, with or without episodes of urgency and urgency incontinence~* Signed informed consent form~Exclusion Criteria:~* Pregnancy, breastfeeding~* Patients requiring self-catheterizations~* Patients unable or unwilling to learn self-catheterisation~* Recent (\<12 weeks) or current treatment with botulinum toxin for any non-urological indication~* Recent (≤ 8 weeks) or current treatment with anticholinergic drugs~* Patients with a positive history or evidence of pelvic / urological abnormality (interstitial cystitis, bladder lithiasis in the 6 months preceding the screening, or any other condition / operation affecting the bladder or prostate)~* Any contraindication to Vesicare®:~  * Hypersensitivity to the active ingredient or to one of the excipients~ * Urinary retention~ * Untreated narrow-angle glaucoma~ * Severe gastrointestinal illness (e.g. toxic megacolon)~ * Myasthenia gravis~ * Severe hepatic failure~ * Hemodialysis~ * Severe renal failure, or liver function disturbances of moderate severity with concomitant treatment with a strong inhibitor of the CYP3A4 isoenzyme, including patients at risk for these diseases.~* Any contraindication to BOTOX®:~  * Known hypersensitivity to the active substance or to one of the excipients~ * Presence of a symptomatic infection at the planned injection site(s)~ * Urinary tract infection at the time of planned treatment~ * Patients who present with acute urinary retention at the time of treatment and who do not regularly use bladder catheterization~ * Patients who do not want and / or cannot, if necessary, perform self-intermittent catheterisation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vesicare (Type: ACTIVE_COMPARATOR): Group 1: will be treated with an anticholinergic (Vesicare® 10 mg per day for 12 weeks)
- Botox (Type: ACTIVE_COMPARATOR): Group 2: will receive an intra-detrusor injection of a low dose of botulinum toxin type A (100 U of BOTOX®).

Based on this trial design, predict the completion outcome and termination type (if applicable).